Enlivex Ltd. (ENLV)
0.6743
-0.02
(-2.64%)
USD |
NASDAQ |
Jun 10, 16:00
0.6743
0.00 (0.00%)
After-Hours: 20:00
Enlivex Enterprise Value : 159.18M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 159.18M |
| June 08, 2026 | 164.31M |
| June 05, 2026 | 163.31M |
| June 04, 2026 | 182.42M |
| June 03, 2026 | 196.55M |
| June 02, 2026 | 196.52M |
| June 01, 2026 | 199.73M |
| May 29, 2026 | 187.12M |
| May 28, 2026 | 176.23M |
| May 27, 2026 | 180.41M |
| May 26, 2026 | 157.14M |
| May 22, 2026 | 165.09M |
| May 21, 2026 | 165.74M |
| May 20, 2026 | 161.77M |
| May 19, 2026 | 162.01M |
| May 18, 2026 | 160.30M |
| May 15, 2026 | 165.83M |
| May 14, 2026 | 168.58M |
| May 13, 2026 | 168.63M |
| May 12, 2026 | 172.64M |
| May 11, 2026 | 171.19M |
| May 08, 2026 | 177.56M |
| May 07, 2026 | 185.41M |
| May 06, 2026 | 192.51M |
| May 05, 2026 | 189.38M |
| Date | Value |
|---|---|
| May 04, 2026 | 197.07M |
| May 01, 2026 | 188.48M |
| April 30, 2026 | 189.38M |
| April 29, 2026 | 185.03M |
| April 28, 2026 | 190.85M |
| April 27, 2026 | 204.21M |
| April 24, 2026 | 205.69M |
| April 23, 2026 | 210.01M |
| April 22, 2026 | 205.71M |
| April 21, 2026 | 203.31M |
| April 20, 2026 | 202.70M |
| April 17, 2026 | 198.80M |
| April 16, 2026 | 205.71M |
| April 15, 2026 | 189.43M |
| April 14, 2026 | 188.48M |
| April 13, 2026 | 193.75M |
| April 10, 2026 | 223.02M |
| April 09, 2026 | 220.19M |
| April 08, 2026 | 216.27M |
| April 07, 2026 | 192.61M |
| April 06, 2026 | 202.15M |
| April 02, 2026 | 220.76M |
| April 01, 2026 | 223.21M |
| March 31, 2026 | 215.56M |
| March 30, 2026 | 208.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 1.979M |
| Brainstorm Cell Therapeutics, Inc. | 9.859M |
| Summit Therapeutics, Inc. | 10.51B |
| PeptiDream Inc. | 710.50M |
| Kezar Life Sciences, Inc. | -11.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.243B |
| Total Expenses (Quarterly) | -1.243B |
| EPS Diluted (Quarterly) | 25.79 |
| Earnings Yield | 3.78K% |
| Normalized Earnings Yield | 262.06 |